Quantcast

DrugRisk Center Announces New Pradaxa Safety Warning

December 22, 2012

The Drug Resource Center is the Web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

Dallas, TX (PRWEB) December 21, 2012

The prescription drug resource center DrugRisk.com is alerting those patients taking the blood thinner Pradaxa that the FDA recently issued a new warning about the safety of the drug. DrugRisk has previously advised patients of conflicting safety reports and rising litigation regarding Pradaxa.

The FDA alert, issued on December 19th, warned against the use of Pradaxa in patients with mechanical heart valves after clinical trials in Europe showed risks of strokes, heart attacks, and blood clots higher than with warfarin.*

With DrugRisk´s goal of improving patient safety through education of the latest drug warnings, recalls, studies and litigation, it was important that this information be passed on to the public, explained DrugRisk representative Ryan Mayer.

DrugRisk had previously advised that the number of patients filing a Pradaxa lawsuit claiming internal bleeding has risen 50% since September.** These cases have been moved to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

The resource center also cautions that experts disagree about the safety of Pradaxa and its relation to dangerous internal bleeding. Last month the FDA updated warnings to say that Pradaxa carries the same risks as warfarin.*** However, the New York Times reported doctors´ concerns the same day that Pradaxa led all other medications for adverse reports and currently has no antidote for internal bleeding.****

Most common among the adverse reports were 6,497 gastrointestinal side effects, 4,910 gastrointestinal hemorrhages (bleeding) and 2,941 central nervous system or cranial hemorrhaging problems. There were also 842 deaths attributed to the drug.

Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*fda.gov/Drugs/DrugSafety/ucm332912.htm

**jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets-By-District-November-2012.pdf

***fda.gov/Drugs/DrugSafety/ucm326580.htm

****nytimes.com/2012/11/03/business/a-rising-anti-stroke-drug-is-tied-to-risk-of-bleeding-deaths.html

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-lawsuit/warnings/prweb10262161.htm


Source: prweb



comments powered by Disqus